These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30963247)

  • 1. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
    Ballester MP; Marti-Aguado D; Fullana M; Bosca-Watts MM; Tosca J; Romero E; Sanchez A; Navarro-Cortes P; Anton R; Mora F; Minguez M
    Int J Colorectal Dis; 2019 Jun; 34(6):1053-1059. PubMed ID: 30963247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
    Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
    BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
    Higgins PD; Rubin DT; Kaulback K; Schoenfield PS; Kane SV
    Aliment Pharmacol Ther; 2009 Feb; 29(3):247-57. PubMed ID: 18945258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
    Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M
    Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis.
    Lee J; Jee SR; Kim HW; Baek DH; Song GA; Moon W; Park SJ; Kim HJ; Lee JH; Park JH; Kim TO;
    PLoS One; 2019; 14(3):e0214129. PubMed ID: 30901362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.
    Oliveira L; Cohen RD
    Drug Des Devel Ther; 2011 Feb; 5():111-6. PubMed ID: 21448448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study.
    Kawakami A; Tanaka M; Nishigaki M; Naganuma M; Iwao Y; Hibi T; Sanada H; Yamamoto-Mitani N; Kazuma K
    J Gastroenterol; 2013 Sep; 48(9):1006-15. PubMed ID: 23208019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
    Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH
    Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.
    Nikolaus S; Schreiber S; Siegmund B; Bokemeyer B; Bästlein E; Bachmann O; Görlich D; Hofmann U; Schwab M; Kruis W
    J Crohns Colitis; 2017 Sep; 11(9):1052-1062. PubMed ID: 28486634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
    Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T;
    BMC Gastroenterol; 2017 Apr; 17(1):47. PubMed ID: 28390410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
    Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
    Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
    Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
    Elkjaer M
    Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
    Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
    Patient; 2012; 5(1):33-44. PubMed ID: 22077619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
    Kane S; Huo D; Aikens J; Hanauer S
    Am J Med; 2003 Jan; 114(1):39-43. PubMed ID: 12543288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
    Fukuda T; Naganuma M; Sugimoto S; Nanki K; Mizuno S; Mutaguchi M; Nakazato Y; Inoue N; Ogata H; Iwao Y; Kanai T
    PLoS One; 2017; 12(11):e0187737. PubMed ID: 29108025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
    Kane SV; Cohen RD; Aikens JE; Hanauer SB
    Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
    Bello C; Belaiche J; Louis E; Reenaers C
    J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.